Phase I/II pharmacokinetic and pharmacogenomic study of UGT1A1 polymorphism in elderly patients with advanced non-small cell lung cancer treated with irinotecan

Clinical Pharmacology and Therapeutics

Volumn 85, Issue 2, 2009, Pages 149-154

  Yamamoto, N ^a   Takahashi, T ^a   Kunikane, H ^b   Masuda, N ^c   Eguchi, K ^d   Shibuya, M ^e   Takeda, Y ^f   Isobe, H ^g   Ogura, T ^h   Yokoyama, A ⁱ   Watanabe, K ^b  

^a SHIZUOKA CANCER CENTER   (Japan)

^b YOKOHAMA MUNICIPAL CITIZEN'S HOSPITAL   (Japan)

^c KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^f NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^g KKR Sapporo Medical Center   (Japan)

^h Kanagawa Prefectural Cardiovascular and Respiratory Center Hospital   (Japan)

ⁱ NIIGATA CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN;

ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DEATH; DIARRHEA; DRUG DOSE ESCALATION; DRUG RESPONSE; DRUG TOLERABILITY; ELDERLY CARE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GENETIC POLYMORPHISM; HUMAN; INTERSTITIAL PNEUMONIA; JAPANESE; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; NEUTROPENIA; PHARMACOGENOMICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

AGED; AGED, 80 AND OVER; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCURONOSYLTRANSFERASE; HUMANS; LUNG NEOPLASMS; MALE; NEUTROPENIA; POLYMORPHISM, GENETIC; TREATMENT OUTCOME;

EID: 58549092760     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2008.152     Document Type: Article

References (27)

1. World Health Organization: Revised Global Burden of Disease (GBD) 2002 Estimates of the World Health Organization, World Health Organization, 2004 〈http://www.who.int/healthinfo/statistics/〉. Accessed 6 August 2007.
2. National Institute of Population and Social Security Research: Population Projections for Japan: 2001-2050, National Institute of Population and Social Security Research, 2002 〈http://www.ipss.go.jp/〉. Accessed 6 August 2007.
3. World Health Organization: Reducing Risks, Promoting Healthy Life: The World Health Report 2002. (Geneva, Switzerland: World Health Reporting, World Health Organization, 2002).
4. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311, 899-909 (1995).
5. Ohe, Y. et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-arm cooperative study in Japan. Ann. Oncol. 18, 317-323 (2007).
6. Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J. Natl. Cancer Inst. 91, 66-72 (1999).
7. Frasci, G. et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 18, 2529-2536 (2000).
8. Gridelli, C. et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J. Natl. Cancer Inst. 95, 362-372 (2003).
9. Kudoh, S. et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J. Clin. Oncol. 24, 3657-3663 (2006).
10. Mathijssen, R.H. et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin. Cancer Res. 7, 2182-2194 (2001).
11. Ma, M.K. & McLeod, H.L. Lessons learned from the irinotecan metabolic pathway. Curr. Med. Chem. 10, 41-49 (2003).
12. Mathijssen, R.H. et al. Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin. Cancer Res. 9, 3246-3253 (2003).
13. Negoro, S. et al. Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br. J. Cancer 88, 335-341 (2003).
14. Chabot, G.G. Clinical pharmacokinetics of irinotecan. Clin. Pharmacokinet. 33, 245-259 (1997).
15. de Forni, M. et al. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res. 54, 4347-4354 (1994).
16. Iyer, L. et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J. Clin. Invest. 101, 847-854 (1998).
17. Innocenti, F. et al. Genetic variants in the UDP- glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol. 22, 1382-1388 (2004).
18. Marcuello, E. et al. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br. J. Cancer 91, 678-682 (2004).
19. Rouits, E., Boisdron-Celle, M., Dumont, A., Guérin, O., Morel, A. & Gamelin, E. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin. Cancer Res. 10 5151-5159 (2004).
20. Beutler, E., Gelbart, T. & Demina, A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc. Natl. Acad. Sci. USA 95, 8170-8174 (1998).
21. International HapMap Project. 〈http://www.hapmap.org/〉.
22. Akaba, K. et al. Neonatal hyperbilirubinemia and mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene: a common missense mutation among Japanese, Koreans and Chinese. Biochem. Mol. Biol. Int. 46, 21-26 (1998).
23. Patrick Therasse et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92, 205-216 (2000).
24. National Cancer Institute: Common Toxicity Criteria, version 2. (Division of Cancer treatment and Diagnosis, National Cancer Institute, Bethesda, MD, 1999). 〈http://www.fda.gov/cder/cancer/toxicityframe.htm〉.
25. Kurita, A. & Kaneda, N. High-performance liquid chromatographic method for the simultaneous determination of the camptothecin derivative irinotecan hydrochloride, CPT-11, and its metabolites SN-38 and SN-38 glucuronide in rat plasma with a fully automated on-line solid-phase extraction system, PROSPEKT. J. Chromatogr. B Biomed. Sci. Appl. 724, 335-344 (1999).
26. Ando, Y. et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 60, 6921-6926 (2000).
27. Sai, K. et al. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin. Pharmacol. Ther. 75, 501-515 (2004).